APLS — Apellis Pharmaceuticals, Inc.

Summary of Apellis Pharmaceuticals Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $200 million for Q4 2025; $1 billion for the full year, including a one-time $275 million payment from a royalty repurchase agreement.
• SYFOVRE Revenue: $155 million for Q4; $587 million for the full year, with a 17% year-over-year increase in total injections despite a decline in revenue due to elevated use of free goods.
• EMPAVELI Revenue: $35 million for Q4; $102 million for the full year, with over 5% market penetration after its first full quarter.
• Operating Expenses: $251 million in Q4, consistent with prior year; expected to rise modestly in 2026 due to new trials and milestone payments.
• Cash Position: $466 million in cash and equivalents, providing flexibility for funding operations.

2. Strategic Updates and Business Highlights

• Focus Areas for 2026:
  • Strengthening SYFOVRE's market leadership in geographic atrophy.
  • Driving growth of EMPAVELI in rare kidney diseases.
  • Advancing an innovative pipeline, including APL-3007 and APL-9099.
• SYFOVRE Initiatives: Introduction of a prefilled syringe and an AI-enabled OCT-F tool to enhance treatment accessibility and workflow efficiency.
• EMPAVELI Launch: Strong uptake in C3G and primary IC-MPGN, with plans to broaden engagement with physicians and enhance patient identification efforts.

3. Forward Guidance and Outlook

• SYFOVRE: Expected to remain a stable revenue stream through 2026, with net pricing anticipated to stay stable and a focus on growth initiatives for 2027.
• EMPAVELI: Positioned for blockbuster status with continued growth expected, though acknowledging potential quarter-to-quarter variability.
• Overall Strategy: Emphasis on disciplined execution and long-term value creation, with a strong balance sheet to support pipeline advancements.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: SYFOVRE's revenue was impacted by increased free goods utilization, which may continue to affect revenue in the near term.
• Market Penetration Challenges: While EMPAVELI has shown strong initial uptake, there are concerns about penetrating more challenging indications like IC-MPGN.
• Competitive Pressures: The potential for competitors to introduce similar products, such as prefilled syringes, could impact market share and growth.

5. Notable Q&A Insights

• EMPAVELI Penetration: Discussion on the potential for reaching 50% penetration in the C3G and IC-MPGN populations, with a focus on steady growth rather than rapid spikes.
• SYFOVRE's 5-Year Data: Highlighted as a significant differentiator, showing that treatment can delay disease progression by approximately 1.5 years, which may lead to increased adoption.
• OCT-F Technology: Expected to enhance understanding of geographic atrophy and support treatment decisions, with plans for broader implementation in retina practices.
• Patient Pipeline Visibility: Strong identification of patients and a growing pipeline for EMPAVELI, with expectations for steady growth moving forward.

This summary encapsulates the key points from the earnings call, providing a holistic view of Apellis Pharmaceuticals' financial performance, strategic direction, and market challenges.